Spots Global Cancer Trial Database for myeloid leukemia
Every month we try and update this database with for myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | NCT03638206 | B-cell Acute Ly... Lymphoma Myeloid Leukemi... Multiple Myelom... Hepatoma Gastric Cancer Pancreatic Canc... Mesothelioma Colorectal Canc... Esophagus Cance... Lung Cancer Glioma Melanoma Synovial Sarcom... Ovarian Cancer Renal Carcinoma | CAR-T cell immu... | 4 Years - 70 Years | Shenzhen BinDeBio Ltd. | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | NCT00543972 | Myeloid Leukemi... | AVE9633 | 18 Years - | Sanofi | |
| Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | NCT00126893 | Myeloid Leukemi... | CC-401 | 18 Years - | Celgene | |
| Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT | NCT01779882 | Myeloid Leukemi... Precursor Myelo... Lymphoid Neopla... | Busulfan-Cyclop... Cyclophosphamid... | 18 Years - 65 Years | University Hospital, Basel, Switzerland | |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | NCT01380756 | Cancer Hematologic Mal... Leukemia Myeloid Leukemi... | Arm 1- Dose Esc... Arm 2- Dose Exp... | 18 Years - | Amgen | |
| Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | NCT03659084 | Myeloid Leukemi... Myelodysplastic... | EXJADE | 18 Years - | Hospices Civils de Lyon | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | NCT00521664 | Myeloid Leukemi... | Prophylactic pl... Therapeutic pla... | 16 Years - 80 Years | Technische Universität Dresden | |
| Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | NCT00967343 | Myeloid Leukemi... Lymphoblastic L... Lymphoma Multiple Myelom... Myelodysplastic... Myeloproliferat... | Donor lymphocyt... | 18 Years - 65 Years | Kiadis Pharma | |
| Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | NCT00422890 | Myeloid Leukemi... Myelodysplastic... | 5-Azacytidin | 18 Years - | Technische Universität Dresden | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | NCT00543972 | Myeloid Leukemi... | AVE9633 | 18 Years - | Sanofi | |
| Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | NCT05035706 | Acute Myeloid L... Myeloid Leukemi... Recurrent Acute... | Biopsy Biospecimen Col... Electronic Heal... Photography | 18 Years - | M.D. Anderson Cancer Center | |
| A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | NCT00521664 | Myeloid Leukemi... | Prophylactic pl... Therapeutic pla... | 16 Years - 80 Years | Technische Universität Dresden | |
| HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | NCT00001748 | Graft vs Host D... Hematologic Neo... Lymphoma Myelodysplastic... Myeloid Leukemi... | Peripheral bloo... | - | National Institutes of Health Clinical Center (CC) | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | NCT00114959 | Myeloid Leukemi... Myeloid Leukemi... Blast Phase Myeloid Leukemi... | Homoharringtoni... Imatinib Mesyla... | 16 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | NCT00543972 | Myeloid Leukemi... | AVE9633 | 18 Years - | Sanofi | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | NCT06235801 | Myeloid Leukemi... | Gilteritinib Momelotinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | NCT01994837 | Acute Myelogeno... AML Acute Myeloid L... | ABT-199 | 18 Years - 99 Years | AbbVie | |
| Frequency and Risk Factors of Acute Myeloid Leukemia | NCT05787951 | Myeloid Leukemi... | Bone marrow asp... | 18 Years - 80 Years | Assiut University | |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot | NCT05871008 | Breast Cancer Hodgkin Lymphom... Kidney Cancer Leukemia Lymphoid Leukem... Multiple Myelom... Myeloid Leukemi... Monocytic Leuke... Prostate Cancer Bladder Cancer | Assessment tool... Assessment tool... | 65 Years - 111 Years | University of Colorado, Denver | |
| Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | NCT00464113 | Chronic Myeloid... Leukemia, Lymph... | XL228 | 18 Years - | Exelixis | |
| NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | NCT02763475 | Acute Myeloid L... Leukemia Myeloid Leukemi... | cyclophosphamid... Fludarabine NK cell infusio... IL-2 | - 21 Years | Instituto de Investigación Hospital Universitario La Paz | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | NCT06429449 | Leukemia Myeloid Leukemi... Monocytic Leuke... | Venetoclax Azacitidine Mitoxantrone | 18 Years - 80 Years | University of Colorado, Denver | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | NCT03760523 | Acute Myeloid L... | Minnelide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia | NCT00718159 | Acute Myeloid L... Essential Throm... | LY573636-sodium | 18 Years - | Eli Lilly and Company | |
| Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | NCT02489929 | Myeloid Leukemi... Myelodysplastic... | blood samples azacytidine | 18 Years - 85 Years | Assistance Publique Hopitaux De Marseille | |
| Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia | NCT00464113 | Chronic Myeloid... Leukemia, Lymph... | XL228 | 18 Years - | Exelixis | |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | NCT04996875 | Advanced System... SM With an Asso... Mast Cell Leuke... Aggressive Syst... | bezuclastinib | 18 Years - | Cogent Biosciences, Inc. | |
| Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | NCT00422890 | Myeloid Leukemi... Myelodysplastic... | 5-Azacytidin | 18 Years - | Technische Universität Dresden | |
| Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype | NCT01066338 | Myeloid Leukemi... | 18 Years - | Samsung Medical Center | ||
| A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) | NCT01994837 | Acute Myelogeno... AML Acute Myeloid L... | ABT-199 | 18 Years - 99 Years | AbbVie | |
| Study of IMC-EB10 in Participant With Leukemia | NCT00887926 | Myeloid Leukemi... | IMC-EB10 | 18 Years - | Eli Lilly and Company | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | NCT06429449 | Leukemia Myeloid Leukemi... Monocytic Leuke... | Venetoclax Azacitidine Mitoxantrone | 18 Years - 80 Years | University of Colorado, Denver | |
| IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | NCT04628338 | Myelodysplastic... Myeloid Leukemi... Allogeneic Stem... | IFN-γ (interfer... | 18 Years - | University of Pittsburgh | |
| Study of IMC-EB10 in Participant With Leukemia | NCT00887926 | Myeloid Leukemi... | IMC-EB10 | 18 Years - | Eli Lilly and Company | |
| Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | NCT03613727 | Lymphoid Leukem... Myeloid Leukemi... Monocytic Leuke... Myelodysplasia | Intravenous (IV... | 18 Years - 77 Years | Virginia Commonwealth University | |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | NCT04260022 | Leukemia, Myelo... Myeloid Leukemi... Chronic Myeloid... Philadelphia Po... B Cell Precurso... | Ascentage Pharm... Blinatumomab | 18 Years - | Ascentage Pharma Group Inc. | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Integrated Actionable Aging Assessment for Cancer Patients Pilot | NCT05871008 | Breast Cancer Hodgkin Lymphom... Kidney Cancer Leukemia Lymphoid Leukem... Multiple Myelom... Myeloid Leukemi... Monocytic Leuke... Prostate Cancer Bladder Cancer | Assessment tool... Assessment tool... | 65 Years - 111 Years | University of Colorado, Denver | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype | NCT01066338 | Myeloid Leukemi... | 18 Years - | Samsung Medical Center | ||
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | NCT05363488 | Myeloid Leukemi... | Bosutinib | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
